X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GLENMARK PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GLENMARK PHARMA CADILA HEALTHCARE/
GLENMARK PHARMA
 
P/E (TTM) x 35.1 13.7 256.1% View Chart
P/BV x 9.1 3.8 235.6% View Chart
Dividend Yield % 0.7 0.3 204.5%  

Financials

 CADILA HEALTHCARE   GLENMARK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
GLENMARK PHARMA
Mar-16
CADILA HEALTHCARE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs4541,262 36.0%   
Low Rs305672 45.3%   
Sales per share (Unadj.) Rs96.1270.6 35.5%  
Earnings per share (Unadj.) Rs14.924.9 59.8%  
Cash flow per share (Unadj.) Rs17.834.4 51.8%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.2 407.6%  
Book value per share (Unadj.) Rs52.3151.3 34.5%  
Shares outstanding (eoy) m1,023.74282.16 362.8%   
Bonus/Rights/Conversions FV5:1--  
Price / Sales ratio x3.93.6 110.5%   
Avg P/E ratio x25.538.9 65.6%  
P/CF ratio (eoy) x21.328.1 75.8%  
Price / Book Value ratio x7.36.4 113.6%  
Dividend payout %21.58.0 267.6%   
Avg Mkt Cap Rs m388,458272,778 142.4%   
No. of employees `00015.410.0 154.0%   
Total wages/salary Rs m13,31713,782 96.6%   
Avg. sales/employee Rs Th6,371.17,614.9 83.7%   
Avg. wages/employee Rs Th862.41,374.8 62.7%   
Avg. net profit/employee Rs Th986.1700.2 140.8%   
INCOME DATA
Net Sales Rs m98,37676,340 128.9%  
Other income Rs m941356 264.2%   
Total revenues Rs m99,31776,696 129.5%   
Gross profit Rs m23,82914,172 168.1%  
Depreciation Rs m3,0222,691 112.3%   
Interest Rs m4861,789 27.2%   
Profit before tax Rs m21,26210,048 211.6%   
Minority Interest Rs m-3000-   
Prior Period Items Rs m50-   
Extraordinary Inc (Exp) Rs m-250-   
Tax Rs m5,7163,028 188.7%   
Profit after tax Rs m15,2267,019 216.9%  
Gross profit margin %24.218.6 130.5%  
Effective tax rate %26.930.1 89.2%   
Net profit margin %15.59.2 168.3%  
BALANCE SHEET DATA
Current assets Rs m44,37659,096 75.1%   
Current liabilities Rs m34,07140,018 85.1%   
Net working cap to sales %10.525.0 41.9%  
Current ratio x1.31.5 88.2%  
Inventory Days Days5475 71.8%  
Debtors Days Days62119 52.3%  
Net fixed assets Rs m47,89639,075 122.6%   
Share capital Rs m1,024282 362.9%   
"Free" reserves Rs m48,74630,281 161.0%   
Net worth Rs m53,51942,703 125.3%   
Long term debt Rs m8,96424,873 36.0%   
Total assets Rs m100,163111,026 90.2%  
Interest coverage x44.76.6 676.3%   
Debt to equity ratio x0.20.6 28.8%  
Sales to assets ratio x1.00.7 142.8%   
Return on assets %15.77.9 197.7%  
Return on equity %28.416.4 173.1%  
Return on capital %34.317.5 195.8%  
Exports to sales %45.343.3 104.6%   
Imports to sales %5.97.4 79.9%   
Exports (fob) Rs m44,53733,044 134.8%   
Imports (cif) Rs m5,8385,672 102.9%   
Fx inflow Rs m44,88136,945 121.5%   
Fx outflow Rs m9,06961,066 14.9%   
Net fx Rs m35,812-24,122 -148.5%   
CASH FLOW
From Operations Rs m19,9383,449 578.2%  
From Investments Rs m-9,039-8,802 102.7%  
From Financial Activity Rs m-9,5276,986 -136.4%  
Net Cashflow Rs m1,372934 146.9%  

Share Holding

Indian Promoters % 74.8 48.3 154.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 6.9 120.3%  
FIIs % 5.9 34.4 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.5 104.8%  
Shareholders   44,069 56,727 77.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK LTD  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Infosys Down 4.1%(09:30 am)

Asian stock markets opened mixed in early trade today. Hong Kong Hang Seng has advanced 143 points and China's Shanghai Composite has gained 9 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 21, 2017 10:31 AM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS